CM
VIR icon

Crestline Management’s Vir Biotechnology VIR Stock Holding History

Crestline Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,500
Closed -$424K – 299
2022
Q1 		$424K Buy
+16,500
New +$489K 0.05% 194

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Crestline Management's VIR Position: Q2 2022 in Review

Crestline Management sold out of Vir Biotechnology (VIR) in Q2 2022, closing a stake of 16,500 shares — an estimated $424K sold.

Crestline Management first reported a position in VIR in Q1 2022 and held it in 1 quarter. The position peaked at $424K in Q1 2022. 212 funds tracked by Wall St. Rank hold VIR as of Q2 2022.

  • Crestline Management reported no remaining Vir Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Crestline Management sold 16,500 Vir Biotechnology shares in Q2 2022, an estimated $424K.
  • Crestline Management first reported a position in Vir Biotechnology in Q1 2022 and held it in 1 quarter.
  • Crestline Management's Vir Biotechnology position peaked at $424K in Q1 2022.
  • 212 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2022.

Based on Crestline Management's 13F filing for Q2 2022, filed 12 Aug 2022.